Seeking Alpha

Seeking Alpha Portfolio App for iPad

1,650 people get MYL articles and Market Currents by email alert.

Get email alerts on MYL »

MYL

Mylan Inc

6/20/2013, 7:36 AM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, October 25, 2012, 5:48 PM Mylan (MYL) may be looking for acquisitions to build upon its product line and expand geographically, and is said to be considering deals valued at “well over” $4B. Key areas it's looking to bolster include specialty drugs and deals to widen its range of delivery, including firms that produce topically applied drugs, which would compliment its already strong core pill-related business. Some targets its considering globally include generic manufacturers in emerging markets, such as Jordanian drug maker Hikma Pharmaceuticals. 1 Comment [Healthcare, Global & FX]
Thursday, October 25, 2012, 7:13 AM Mylan Laboratories (MYL): Q3 EPS of $0.83 beats by $0.06. Revenue of $1.81B (+15% Y/Y) beats by $40M. (PR) Comment! [Earnings, Healthcare]
Thursday, October 25, 2012, 12:05 AM Notable earnings before Thursday’s open: ABB, AET, AUO, AVT, AZN, BEN, BG, BIIB, CAB, CCE, CELG, CL, CME, CMS, CNX, COP, CRR, CS, CVE, D, DBD, DDD, DNKN, EQT, GG, GTI, HERO, HOT, HSY, IMAX, IP, JBLU, JNS, LINE, LKQ, MCK, MJN, MO, MYL, NBL, NOV, NS, NVS, NXPI, NYT, O, ORI, OXY, PCAR, PCP, PDS, PG, PHM, POT, PTEN, RCL, ROC, RTN, RYN, S, SHW, SPG, SWI, TKR, TSM, TZOO, UA, UAL, VLY, VPHM, XEL, ZMH Comment! [Earnings]
Wednesday, October 24, 2012, 5:30 PM Notable earnings before Thursday’s open: ABB, AET, AUO, AVT, AZN, BEN, BG, BIIB, CAB, CCE, CELG, CL, CME, CMS, CNX, COP, CRR, CS, CVE, D, DBD, DDD, DNKN, EQT, GG, GTI, HERO, HOT, HSY, IMAX, IP, JBLU, JNS, LINE, LKQ, MCK, MJN, MO, MYL, NBL, NOV, NS, NVS, NXPI, NYT, O, ORI, OXY, PCAR, PCP, PDS, PG, PHM, POT, PTEN, RCL, ROC, RTN, RYN, S, SHW, SPG, SWI, TKR, TSM, TZOO, UA, UAL, VLY, VPHM, XEL, ZMH 1 Comment [Earnings]
Wednesday, August 22, 2012, 5:12 PM Pfizer (PFE) and Mylan (MYL) agree to an exclusive long-term strategic collaboration to develop, manufacture, distribute and market generic drugs in Japan. Under the terms of the agreement, PFE will focus on the commercialization of the combined generics portfolio, plus marketing and sales. MYL will manage operations, R&D and manufacturing. 1 Comment [Healthcare, Global & FX]
Friday, August 17, 2012, 1:38 PM Mylan (MYL -0.7%) receives final approval with 180 days of generic marketing exclusivity from the FDA for its Pioglitazone Tablets, the generic versions of Takeda Pharmaceutical's Actos Tablets and Actoplus Met Tablets. The pills are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Comment! [Healthcare]
Friday, August 10, 2012, 12:30 PM Mylan's (MYL +0.5%) subsidiary, Mylan Pharmaceuticals, has received final FDA approval for its Modafinil Tablets, the generic version of Teva's (TEVA +0.2%) Provigil Tablets. The drug is designed to improve wakefulness in adult patients with narcolepsy, obstructive sleep apnea and shift work disorder. Comment! [Healthcare]
Friday, August 3, 2012, 3:33 PM The FDA approves the first generic versions of Singulair for use in adults and children to control asthma symptoms and to help relieve symptoms of indoor and outdoor allergies. Endo Pharmaceuticals (ENDP +3.2%), Mylan (MYL +4.2%) and Teva Pharmaceuticals (TEVA -0.6%) have all been given the go-ahead. Comment! [Healthcare]
Thursday, August 2, 2012, 11:13 AM Gilead Sciences (GILD +8.3%) says it plans to partner with Mylan (MYL -1.5%), Ranbaxy Laboratories (RBXZF.PK) and Strides Arcolab to promote access to generic versions of Gilead's HIV medicine containing Emtricitabine in developing countries. The drug is marketed by GILD under the brand names Emtriva and Truvada. WHO guidelines recommend the drug as preferred components of first and second line HIV therapy. Comment! [Healthcare, On the Move, Global & FX]
Monday, July 30, 2012, 6:12 AM EU competition authorities charge Teva (TEVA), France's Servier, Mylan Labs (MYL) and three other companies with blocking generic perindopril drugs from entering the market. Perindopril is used to treat hypertension, and to help prevent problems after heart attacks and procedures. (PR) Comment! [Healthcare]
Thursday, July 26, 2012, 8:39 AM Mylan Labs (MYL): Q2 EPS of $0.6 beats by $0.05. Revenue of $1.69B (+7.4% Y/Y) beats by $0.03B. Shares +2.6% premarket. (PR) Comment! [Earnings, Healthcare, On the Move]
Thursday, July 26, 2012, 12:05 AM Notable earnings before Thursday’s open: ABB, ABC, ABX, AGCO, ALKS, ALU, AMLN, AZN, BC, BMS, BSX, BWA, CAM, CELG, CL, CME, CMS, CNX, COV, DAN, DDD, DNKN, DOW, DPS, EQT, ESV, FLIR, FNP, GG, GNC, GTI, HOT, HSY, IMAX, IP, IPG, IRM, IVZ, JNS, KMB, LINE, MCO, MHP, MJN, MMM, MYL, NBL, NEE, NOV, ORI, OXY, PCP, PCS, PHM, PLD, POT, PTEN, RCL, RTN, S, TKR, UAL, UTX, VTR, WEC, WM, WPI, XOM, ZMH Comment! [Earnings]
Wednesday, July 25, 2012, 5:30 PM Notable earnings before Thursday’s open: ABB, ABC, ABX, AGCO, ALKS, ALU, AMLN, AZN, BC, BMS, BSX, BWA, CAM, CELG, CL, CME, CMS, CNX, COV, DAN, DDD, DNKN, DOW, DPS, EQT, ESV, FLIR, FNP, GG, GNC, GTI, HOT, HSY, IMAX, IP, IPG, IRM, IVZ, JNS, KMB, LINE, MCO, MHP, MJN, MMM, MYL, NBL, NEE, NOV, ORI, OXY, PCP, PCS, PHM, PLD, POT, PTEN, RCL, RTN, S, TKR, UAL, UTX, VTR, WEC, WM, WPI, XOM, ZMH Comment! [Earnings]
Wednesday, July 18, 2012, 11:43 AM Somaxon (SOMX +83%) soars this morning - after initially surging over 150% in pre-open trading - on the back of yesterday's announcement of its litigation settlement over Silenor with Mylan (MYL +0.8%) and Par Pharmaceuticals. The company added that it sees higher Q2 net sales for Silenor, now seeing revenue of approximately $2.8M to $2.9M, up from reported sales of $2.7M in Q1. Comment! [Healthcare, On the Move]
Tuesday, July 17, 2012, 4:30 PM Somaxon Pharmaceuticals (SOMX) settles its patent litigation suit with Mylan (MYL) and Par Pharmaceutical (PRX) involving Silenor 3 mg and 6 mg tablets. The settlement grants MYL the exclusive right to begin selling a generic version of Silenor on January 1, 2020, and PRX the right to begin selling a generic version 180 days after a third party generic version is first sold in the U.S. under a license from Somaxon. Comment! [Healthcare]
Sunday, June 24, 2012, 9:07 AM Teva Pharmaceutical (TEVA) is +10.5% in Tel Aviv following the favorable ruling on its Copaxone patent in a case against Momenta (MNTA) and Mylan (MYL). While industry watchers had assumed Teva would prevail, with ~35% of its EPS at risk, a hearty sigh of relief isn't surprising. 11 Comments [Top Stories, On the Move, Healthcare]